Incyte Announces FDA Approval of Jakafi XR™ (Ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Key Takeaways

• Jakafi XR approved for MF, PV, and steroid‑refractory GVHD
• Once‑daily 55 mg tablet is bioequivalent to 25 mg BID regimen
• Expands Incyte’s hematology portfolio, targeting adult and pediatric patients
• IncyteCARES program offers financial aid and education for eligible patients
• Safety profile mirrors existing Jakafi, with common cytopenia and infection risks

Pulse Analysis

The FDA’s green light for Jakafi XR marks a pivotal shift in the treatment landscape for myeloproliferative neoplasms and graft‑versus‑host disease. By reformulating ruxolitinib into a 55 mg extended‑release tablet taken once daily, Incyte addresses a long‑standing adherence hurdle associated with the twice‑daily schedule of the original product. Bioequivalence studies confirm comparable steady‑state exposure, meaning patients can expect the same therapeutic benefit while simplifying their daily routine—a factor that often translates into better outcomes in chronic oncology settings.

Clinically, the approval broadens therapeutic options across three distinct indications. For intermediate‑ or high‑risk myelofibrosis and hydroxyurea‑intolerant polycythemia vera, the once‑daily regimen aligns with the disease’s chronic nature, potentially reducing pill burden and clinic visits. The inclusion of steroid‑refractory acute and chronic GVHD, extending to patients 12 years and older, is especially noteworthy, as it offers a targeted JAK1/2 inhibition strategy where few alternatives exist. Safety data remain consistent with the established Jakafi profile, emphasizing cytopenias and infection risk, which clinicians will continue to monitor closely.

From a business perspective, Jakafi XR reinforces Incyte’s leadership in hematology and positions the company to capture additional market share in a competitive JAK‑inhibitor space dominated by Novartis’s Jakavi and emerging oral agents. The launch is supported by IncyteCARES, a comprehensive patient‑access program designed to mitigate financial barriers and improve uptake. As insurers evaluate cost‑effectiveness, the convenience of a single daily tablet could drive formulary preference, bolstering revenue streams while the broader pipeline of next‑generation therapies promises sustained growth. The approval thus serves both patients—through a more manageable regimen—and investors, by expanding Incyte’s product portfolio in high‑need, high‑value therapeutic areas.